01/01/1985 - "Fifty patients with drug-refractory (failed 7 +/- 2 other drug trials) sustained ventricular tachycardia or fibrillation were treated with oral lorcainide. "
07/01/1981 - "[Clinical-electrophysiological study of the effect of lorcainide on induction of ventricular tachycardia (author's transl)]."
01/01/1990 - "[The effects of lorcainide on the ECG pattern and left ventricular function in a patient with recurrent ventricular tachycardia]."
05/01/1987 - "Lorcainide did not suppress group mean PVDs per hour, pairs, or ventricular tachycardia. "
04/01/1987 - "Lorcainide for the treatment of refractory ventricular tachycardia: clinical and electrophysiologic results."
|2.||Cardiac Arrhythmias (Arrythmia)
02/01/1987 - "A decrease in arrhythmia frequency could be correlated to plasma lorcainide concentration in the majority of patients, and it was noted that at least 0.1 mg/L of lorcainide was required for the presence of an antiarrhythmic effect. "
01/01/1986 - "According to the data of the arrhythmia analyses (30 patients) the most important electrophysiological effects of lorcainide are: increase of the effective refractory period of the atria and ventricles; prolongation of the conduction time in the His bundle; prolongation of the refractory period and conduction of the accessory pathways. "
08/13/1984 - "Management of malignant ventricular arrhythmia--experience with lorcainide."
08/13/1984 - "Lorcainide for high-frequency ventricular arrhythmia: preliminary results of a short-term double-blind and placebo-controlled crossover study and long-term follow-up."
01/01/1983 - "Lorcainide disposition kinetics in arrhythmia patients."
04/01/1982 - "Randomized double-blind placebo controlled crossover trial documenting oral lorcainide efficacy in suppression of symptomatic ventricular tachyarrhythmias."
01/01/1987 - "Long-term maintenance therapy prevented new attacks of tachyarrhythmia for an average period of nine (5-15) months in all seven patients who tolerated lorcainide administration. "
01/01/1986 - "Lorcainide has a very promising antiarrhythmic effect in the suppression of tachyarrhythmias with accessory pathway conduction, too."
06/01/1984 - "Lorcainide in patients with refractory ventricular tachyarrhythmia."
06/01/1983 - "The tachycardia zone was unaffected by lorcainide. "
|4.||Ventricular Premature Complexes (Premature Ventricular Contraction)
02/16/1980 - "Lorcainide reduced the frequency of ventricular ectopic beats by more than 70% and 90% in 17 and 11 of the patients respectively. "
11/30/1984 - "In a randomized double-blind cross-over trial, the effectiveness of lorcainide at a dosage of three times 100 mg/d by mouth was compared with that of a placebo for the treatment of subjectively disturbing stable ventricular extrasystoles (VES), using 48-hour continuous ECG monitoring. "
11/30/1984 - "[Lorcainide in stable ventricular extrasystole. "
06/01/1983 - "Control of ventricular ectopic beats with intravenous lorcainide maintained by oral doses."
04/01/1982 - "Lorcainide, a new antiarrhythmic drug, was given to 10 patients with frequent (greater than 1/min) premature ventricular contractions (PVCs) on a baseline 24-hour Holter monitor. "
04/01/1986 - "Lorcainide was tested acutely in all 38 patients and prevented ventricular tachycardia (VT) or ventricular fibrillation (VF) induction in 14 patients and failed in 24 (efficacy rate 37%). "
06/01/1984 - "Lorcainide, a new antiarrhythmic agent with local anesthetic or membrane-stabilizing properties similar to those of quinidine, was tested in 76 patients with diverse types of heart disease and recurrent ventricular tachycardia or ventricular fibrillation. "
06/01/1981 - "4 In Langendorff-perfused guinea-pig hearts, only lorcainide provided complete protection against ouabain-induced ventricular fibrillation, while 6 of 6, 3 of 6 and 2 of 6 hearts fibrillated in the presence of encainide, lignocaine and ORG 6001 respectively, but with infusion durations significantly higher than control. "
|5.||Ouabain (G Strophanthin)
|1.||Implantable Defibrillators (Implantable Cardioverter-Defibrillator)
|2.||Drug Therapy (Chemotherapy)